Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T29649
(Former ID: TTDI01555)
|
|||||
| Target Name |
Leukotriene receptor (LTR)
|
|||||
| Synonyms |
Human leukotriene receptor
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Asthma [ICD-11: CA23] | |||||
| 2 | Bacterial infection [ICD-11: 1A00-1C4Z] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 4 Clinical Trial Drugs | + | ||||
| 1 | Ontazolast | Drug Info | Phase 2 | Asthma | [2] | |
| 2 | PIRODOMAST | Drug Info | Phase 2 | Asthma | [3] | |
| 3 | SR-2640 | Drug Info | Phase 2 | Asthma | [4] | |
| 4 | WF-11605 | Drug Info | Phase 1 | Bacterial infection | [5] | |
| Discontinued Drug(s) | [+] 7 Discontinued Drugs | + | ||||
| 1 | FK-664 | Drug Info | Discontinued in Phase 2 | Cardiac disease | [6] | |
| 2 | SK&F-S-106203 | Drug Info | Discontinued in Phase 2 | Asthma | [7] | |
| 3 | ABT-080 | Drug Info | Discontinued in Phase 1 | Asthma | [9] | |
| 4 | NZ-107 | Drug Info | Discontinued in Phase 1 | Asthma | [10] | |
| 5 | SMP-028 | Drug Info | Discontinued in Phase 1 | Asthma | [11] | |
| 6 | ICI-198615 | Drug Info | Terminated | Asthma | [12], [13] | |
| 7 | Tipredane | Drug Info | Terminated | Allergy | [14] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Modulator | [+] 12 Modulator drugs | + | ||||
| 1 | Ontazolast | Drug Info | [15] | |||
| 2 | PIRODOMAST | Drug Info | [16] | |||
| 3 | SR-2640 | Drug Info | [1] | |||
| 4 | WF-11605 | Drug Info | [17] | |||
| 5 | FK-664 | Drug Info | [18] | |||
| 6 | SK&F-S-106203 | Drug Info | [19] | |||
| 7 | ABT-080 | Drug Info | [20] | |||
| 8 | NZ-107 | Drug Info | [21] | |||
| 9 | SMP-028 | Drug Info | [22] | |||
| 10 | ICI-198615 | Drug Info | [23] | |||
| 11 | Tipredane | Drug Info | [24] | |||
| 12 | MAR--99 | Drug Info | [25] | |||
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Effect of the leukotriene LTD4/LTE4 antagonist, SR 2640, in ulcerative colitis: an open clinical study. Prostaglandins Leukot Essent Fatty Acids. 1991 Mar;42(3):181-4. | |||||
| REF 2 | A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother Pharmacol. 1999;44(3):259-65. | |||||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000038) | |||||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3329). | |||||
| REF 5 | Effect of WF11605, a novel LTB4 antagonist on galactosamine-induced hepatitis in rats. Ensho. ISSN:0389-4290, VOL.12, NO.4, PAGE.373-377, (1992). | |||||
| REF 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001589) | |||||
| REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000042) | |||||
| REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005124) | |||||
| REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009466) | |||||
| REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000068) | |||||
| REF 11 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024745) | |||||
| REF 12 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3358). | |||||
| REF 13 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002386) | |||||
| REF 14 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003182) | |||||
| REF 15 | Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance. Eur J Med Res. 1997 Apr 21;2(4):159-64. | |||||
| REF 16 | Antiallergy activity of Sch 37224, a new inhibitor of leukotriene formation. J Pharmacol Exp Ther. 1988 Dec;247(3):997-1003. | |||||
| REF 17 | WF11605, an antagonist of leukotriene B4 produced by a fungus. II. Structure determination. J Antibiot (Tokyo). 1992 May;45(5):704-8. | |||||
| REF 18 | US patent application no. 7,175,854, Pharmaceutical preparation comprising an active dispersed on a matrix. | |||||
| REF 19 | Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig. Pulm Pharmacol. 1991;4(3):177-89. | |||||
| REF 20 | An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010 February; 10(1): 60-66. | |||||
| REF 21 | Effects of NZ-107 on tracheal responses to adenosine in the guinea pig. Jpn J Pharmacol. 1991 May;56(1):79-84. | |||||
| REF 22 | Effect of SMP-028 on steroidogenesis in rats; mechanism of toxicological events on endocrine organs of rats. Toxicol In Vitro. 2014 Apr;28(3):397-402. | |||||
| REF 23 | In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther. 1987 Nov;243(2):548-56. | |||||
| REF 24 | New drugs for asthma. Nat Rev Drug Discov. 2004 Oct;3(10):831-44. | |||||
| REF 25 | Effect of 1,6-dihydro-2[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidineca rboxyli c acid on ethanol-induced microvascular injury in rats. Arzneimittelforschung. 1996 Aug;46(8):779-83. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.